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ABSTRACT
Mutations in SOX9, a gene essential for chondrocyte
differentiation cause the human disease
campomelic dysplasia (CD). To understand how
SOX9 activates transcription, we characterized the
DNA binding and cell-free transcription ability of
wild-type SOX9 and a dimerization domain SOX9
mutant. Whereas formation of monomeric mutant
SOX9–DNA complex increased linearly with
increasing SOX9 concentrations, formation of a
wild-type SOX9–DNA dimeric complex increased
more slowly suggesting a more sigmoidal-type
progression. Stability of SOX9–DNA complexes,
however, was unaffected by the dimerization
mutation. Both wild-type and mutant SOX9
activated transcription of a naked Col2a1 DNA
template. However, after nucleosomal assembly,
only wild-type and not the mutant was able to
remodel chromatin and activate transcription of
this template. Using a cell line, in which the Col2a1
vector was stably integrated, no differences were
seen in the interactions of wild-type and mutant
SOX9 with the chromatin of the Col2a1 vector
using ChIP. However, the mutant was unable to
activate transcription in agreement with in vitro
results. We hypothesize that the SOX9 dimerization
domain is necessary to remodel the Col2a1 chroma-
tin in order to allow transcription to take place.
These results further clarify the mechanism that
accounts for CD in patients harboring SOX9 dimer-
ization domain mutations.
INTRODUCTION
Most skeletal elements are formed by endochondral ossi-
ﬁcation involving a cartilage intermediate. In the multistep
process of chondrogenesis, committed mesenchymal cells
ﬁrst condense and then diﬀerentiate into chondrocytes to
form cartilage. Diﬀerentiation into chondrocytes is
associated with activation of a repertoire of cartilage-
speciﬁc extracellular matrix genes such as collagen types
II, IX and XI, CD-Rap, aggrecan, matrilin1 and others.
The collagen type X gene is expressed later, when chon-
drocytes become hypertrophic (1–3).
The role of SOX9 in chondrogenesis was suggested ﬁrst
by the identiﬁcation of heterozygous mutations in and
around the SOX9 gene in the human genetic disease
campomelic dysplasia (CD), a generalized disease of car-
tilage causing severe skeletal malformations often
associated with XY male-to-female sex reversal (4,5).
SOX9 belongs to the Sox family of transcriptional regula-
tors characterized by a high-mobility group (HMG) box
DNA binding domain ﬁrst identiﬁed in the
sex-determining factor SRY. In mouse embryos, Sox9 is
expressed in all chondroprogenitor cells and all chondro-
cytes, but its expression is abolished in hypertrophic chon-
drocytes and there is no expression of Sox9 in osteoblasts.
SOX9 is also expressed in and required for the diﬀerenti-
ation of a discrete number of other cell types (6–8).
Heterozygous Sox9 mouse mutants duplicate the skeletal
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demonstrated that SOX9 was required for cartilage for-
mation. Indeed, in mouse chimeras, Sox9
 /  cells were
excluded from chondrogenic mesenchymal condensations,
but were present as juxtaposed mesenchyme that did not
express chondrocyte-speciﬁc markers (10). Moreover, no
cartilage developed in teratomas derived from Sox9
 / 
embryonic stem (ES) cells (10). Experiments using the
Cre/loxP recombination system to generate mouse
embryos, in which Sox9 was either ablated in undiﬀeren-
tiated mesenchymal cells of limb buds or inactivated after
chondrogenic mesenchymal condensations formed,
demonstrated that Sox9 was required during sequential
steps of the chondrocyte diﬀerentiation pathway (11).
A common feature in chondrocyte-speciﬁc enhancers of
cartilage genes such as those of collagen types II, IX and
XI, CD-Rap, aggrecan and matrilin1 is the presence of
pairs of SOX9 binding sequences. These enhancers are
activated by SOX9 in transfection experiments, and mu-
tations in these enhancers that prevent SOX9 binding
abolish their chondrocyte-speciﬁc activity in DNA trans-
fections and in transgenic mice (12–21). A 7-bp consensus
DNA element (A/T)(A/T)CAA (A/T)G has been
identiﬁed as a recognition element for SOX proteins,
which interact with the minor groove of DNA. DNA
binding of SOX proteins is accompanied by a bend in
the DNA. SOX9 also harbors a transcription activation
domain located at the C-terminus of the protein. In several
transcriptional enhancers found in genes involved in
chondrogenesis, SOX9 forms a dimer with pairs of sites
arranged in an inverted repeat conﬁguration (16,18). In
several of these enhancers, mutations in one or the other
site of the pair abolished activity of the enhancer
(16,18,22).
SOX9 mutations have been identiﬁed in patients with
CD in a conserved region preceding the HMG DNA
binding domain (23,24). In contrast to wild-type SOX9,
which forms a dimeric SOX9–DNA complex with pairs of
binding sites in chondrocyte enhancers, mutant SOX9
binds to these DNAs mainly as a monomer. In transient
expression experiments, activation of these enhancers in
the genes for collagen types II, IX and XI and CD-Rap
was much lower with the SOX9 mutants than with
wild-type SOX9. However, activation of reporters con-
taining the promoters of the SF1 and Amh genes, which
are expressed in Sertoli cells of male gonads, was not
aﬀected by the mutant SOX9, suggesting that SOX9 di-
merization is required for chondrogenesis but not for sex
determination (23,24).
To improve our understanding of the role of SOX9 in
transcription, we used wild-type and dimerization mutant
recombinant SOX9 polypeptides to further characterize
their binding to DNA and to examine their ability to
activate transcription in vitro in a cell-free system with
both naked DNA and chromatin-assembled templates.
Wild-type recombinant SOX9 activated a Col2a1
promoter–enhancer template both as naked DNA and
after assembly of this DNA with nucleosomes. In
contrast, the dimerization domain SOX9 mutant activated
the naked Col2a1 DNA template but unlike wild-type
SOX9 was unable to activate this template when
assembled into chromatin.
MATERIALS AND METHODS
Plasmid construction
The p89/4 48bp Col2a1 luciferase construction and its
mutant MA6 were described previously (13). Plasmid p120
containing a segment of the mouse a1(III) collagen gene
promoter was used as internal control in transcription
assays (25). Wild-type and dimerization-deletion mutant
human SOX9 coding sequences, linked to a Flag-tag at
their N-terminus, were cloned into the pBACgus-2cp
between NheI and Not1 sites and then transferred into
baculovirus DNA (Figure 1A). The 10-amino acid
deletion (66–75) was introduced into the construct
using PCR. These Flag-tagged SOX9 were also linked to
3 HA tag at the C-terminus and cloned into EcoRI and
BamHI sites of modiﬁed pEGFP-C1 mammalian expres-
sion vector (Clontech) that was deleted of the EGFP
sequence. The sequences of all constructs were veriﬁed
by DNA sequencing.
Generation of recombinant proteins
Wild-type and mutant SOX9 polypeptides were generated
in Sf9 cells using a baculovirus expression system
(Novagen). Sf9 cells were grown in suspension to a
density of 2 10
6 cells per ml and were infected with wt-
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Figure 1. Comparison of DNA binding of puriﬁed wild-type and
mutant SOX9 proteins to the Col2a1 enhancer. (A) Schematic repre-
sentation of the proteins used in the study: wild-type SOX9 and dimer-
ization mutant SOX9. (H, His-tag; S, S-tag; F, FLAG-tag; D,
dimerization domain; HMG, HMG box; TA, transcription activation
domain). (B) SDS–PAGE analysis of puriﬁed recombinant SOX9 poly-
peptides. (C) Amounts of DNA–protein complexes computed using a
Phosphoimager from four sets of EMSAs with a 31-bp oligonucleotide
probe corresponding to the 30-end of the 48-bp Col2a1 intron 1
enhancer and increasing amounts of wild-type (wt) or mutant SOX9
proteins.
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cells were collected by centrifugation and resuspended in a
buﬀer containing 10mM Tris–HCl, pH 7.9, 0.5M NaCl,
0.1% NP-40, 5mM 2b-ME and 1mM phenylmethyl-
sulfonyl ﬂuoride (PMSF).
The cells were sonicated on ice for four times for a
duration of 15s with 45s interruption. After centrifuga-
tion, the supernatant was loaded on a nickel-nitrotriacetic
acid agarose column (Qiagen Inc.,Valencia, CA, USA)
previously equilibrated in the buﬀer described above.
The resin was washed with a buﬀer containing 20mM
Tris–HCl, pH 7.9, 10mM KCl, 5mM 2b-ME and
0.5mM PMSF. Twenty millimolar imidazole was added
to the wash buﬀer and used for additional wash of the
resin. The proteins were eluted with the wash buﬀer con-
taining 200mM imidazole. The fractions were collected
and the purity of proteins was veriﬁed by Coomassie
blue staining after SDS gel electrophoresis (Figure 1B).
Nuclear extracts
HeLa cells were grown in suspension in Joklik medium
supplemented with 5% calf serum at a density of
0.8 10
6 cells/ml. Nuclear extracts were prepared as
described (26).
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assays (EMSAs) were per-
formed using a Col2a1 enhancer probe containing either a
wild-type or mutated SOX9 binding site. The upper
strands were as follows: Wild-type (50-GGCGCTTGAG
AAAAGCCCCATTCATGAGAGG-30); Site 1 mutant
(50-GGCGCTTGAGATTAGCCCCATTCATGAGAG
G-30); and Site 2 mutant (50-GGCGCTTGAGAAAAGC
CCGAATCCTGAGAGG-30). The binding reactions were
carried out with 5 fmol of
32P-end-labeled probe in a
buﬀer containing 20mM HEPES (pH 7.9), 50mM KCl,
10% glycerol, 0.1% (vol/vol) Nonidet P-40, 0.5mM
EDTA, 4mM dithiothreitol (DTT), 1mM PMSF and
30mg of bovine serum albumin. Puriﬁed proteins were
assayed in the presence of 20ng of poly(dG–dC).
Reaction mixtures (25ml) were incubated for various
times at room temperature and fractionated on a 5% poly-
acrylamide gel in a 0.5  TGE buﬀer at 150V. All experi-
ments were performed three times providing very similar
results.
Chromatin assembly
Chromatin assembly reactions were performed as
described previously (27,28). In a typical 60-ml assembly
reaction, 30ml of Drosophila embryo S190 extract was
incubated with 1.6mg of puriﬁed core histones in RO
buﬀer (10mM HEPES, pH 7.5, 10mM KCl, 0.5mM
EGTA, 10% glycerol, 10mM B-glycerophosphate, 1mM
DTT, 0.2mM PMSF) at room temperature for 30min. To
this sample 10  ATP mix (300mM creatine phosphate,
30mM ATP, 1mg of creatine phosphokinase and 26mM
MgCl2) was added and incubated for 5min on ice. One
microgram of plasmid DNA (preincubated or not with
SOX9 for 20min on ice) was then added, and chromatin
assembly was allowed to proceed for 4.5h at 27 C. To
assay the quality of chromatin, a sample chromatin was
digested with micrococcal nuclease (Mnase) and the DNA
was subjected to electrophoresis on a 1.5% agarose gel.
In vitro transcription
Col2a1 promoter constructs, either as naked plasmid
DNA or as chromatin-reconstituted DNA were used. An
aliquot of chromatin assembly reaction containing 175ng
of DNA (not preincubated with SOX9) or 300ng of naked
DNA were incubated with SOX9 for 20min on ice prior to
transcription. Aliquots of chromatin assembly reaction
containing 175ng of DNA (incubated with SOX9 prior
to chromatin assembly) were used directly for transcrip-
tion. In a typical 25ml transcription reaction, DNA was
incubated with transcription mix (1% polyvinyl alcohol,
1% polyethylene glycol, 1mM NTPs, 5mM MgCl2 ﬁnal
concentration), HeLa nuclear extracts and 200ng of
naked plasmid DNA p120 as an internal control
template. Incubations were carried out at 27 C for 1h
and reactions were stopped by adding 75ml of a solution
containing 0.4M NaOAc, pH 5.2 and 1% SDS. RNAs
were puriﬁed by phenol/chloroform extraction, chloro-
form extraction and ethanol precipitation with glycogen
as carrier. RNAs were subjected to primer extension using
Avian Myeloblastosis Virus (AMV) reverse transcriptase
in presence of
32P-labeled primers corresponding to a
segment of the luciferase reporter gene and to a
sequence in the chloramphenicol acetyltransferase gene.
Primer extension products were fractionated by electro-
phoresis in 7M urea, 8% polyacrylamide gel in 1  TBE
buﬀer, analyzed by autoradiography and quantiﬁed with
Phosphorimager. All experiments were repeated at least
three times and provided similar results.
Mnase digestion
Immediately after chromatin assembly, an aliquot of the
chromatin assembly reaction (containing 175ng of DNA)
was digested with Mnase (0.12U/ml ﬁnal concentration)
in presence of 3mM of CaCl2 for 20min at room tempera-
ture. The digestion was stopped by adding stop buﬀer
(EDTA 175mM, RNAse A-DNAse-free 0.05mg/ml in
TE) for 15min at 37 C. This was followed by proteinase
K treatment (50mg/ml ﬁnal concentration) for 15min at
37 C. The DNA was puriﬁed by phenol–chloroform ex-
traction, chloroform extraction and ammonium acetate–
ethanol precipitation with glycogen as carrier. DNA was
subjected to electrophoresis on a 1.5% agarose gel.
SOX9 interaction with chromatin DNA
After incubation of chromatin DNA with recombinant
SOX9, Mnase digestion, and DNA extraction, the DNA
corresponding to the Col2a1 promoter/enhancer was sub-
jected to linear ampliﬁcation using a
32P-labeled primer
corresponding to a segment of the luciferase reporter
gene. DNA (100ng), the reaction buﬀer and Vent (exo
 )
polymerase (New England Biolabs) were added to a
mixture containing the labeled oligonucleotide primer.
The extension program was run ﬁrst for 4min at 95 C,
followed by eight cycles of 1min at 94 C, 3min of anneal-
ing at 45 C, 30s at 74 C and hold at 18 C. After NaOAc–
6020 Nucleic Acids Research, 2010,Vol.38, No. 18EtOH precipitation, the DNA was analyzed on a 6%
sequencing gel using a NaOAc gradient (top buﬀer: 0.5 
TBE; bottom buﬀer: 1  TBE/1M NaOAc).
Establishment of stable cell lines
The tandemly ligated Col2a1 48-bp enhancer and Col2a1
minimum promoter were inserted 50 to the ﬁreﬂy luciferase
gene of pGL4.18 plasmid (Promega). Then the
puromycin-resistant gene was inserted into a site located
50 to the multimerized Col2a1 enhancer to generate
Col2a1-F.Luc-puro
r. The HEK293T cells (293T), derived
from human embryonic kidney cells, were transfected with
the Col2a1-F.Luc-puro
r plasmid by use of Fugene 6
(Roche) according to the manufacturer’s protocol, and
the stably transfected cells were selected by use of 2mg/
ml puromycin hydrochloride. Four colonies among the
puromycin-resistant colonies were picked up and
expanded. The clone that had the highest luciferase
activity in the presence of ectopic SOX9 was used in the
experiment of Figure 7.
Reporter assay
The 1.5 10
5 293T cells, stably tranfected with Col2a1-
F.Luc-puro
r plasmid, were inoculated into each well of
12-well plates. After 24-h incubation, the cells were trans-
fected with 0.25mg/well of a vector expressing wild-type
SOX9 or mutant SOX9 by use of Fugene 6. After 40-h
incubation, the ﬁreﬂy luciferase activities were measured
by the luciferase assay system (Promega).
Chromatin immunoprecipitation and quantitative PCR
The 293T cells that had been stably transfected with the
Col2a1-F.Luc-puro
r plasmid (described above) were used
in the chromatin immunoprecipitation experiment (ChIP).
ChIP was performed according to ChIP assay kit
(Millipore Co., Ltd). Approximately 1 10
7 cells were
transfected with 5mg of empty vector, wild-type SOX9
or dimerless mutant SOX9 plasmid by use of Fugene 6
(Roche Diagnostics Co., Ltd) and cultured for 40h.
Subconﬂuent cells were treated with 1% formaldehyde
in serum-free medium for 20min followed by a treatment
with 125mM glycine. Cells were washed with cold PBS,
resuspended with 10mM Tris–HCl, pH 7.4, 3mM MgCl2,
0.1% Nonidet P40, 1mM PMSF and EDTA-free protease
inhibitor cocktail (Roche Diagnostics Co., Ltd) and
prepared by centrifugation for nuclei isolation. Nuclear
extracts were sonicated to shear the DNA to an average
length of about 500bp and diluted to the ﬁnal concentra-
tion of 0.05% SDS. To reduce non-speciﬁc background,
sheared chromatin was precleared with 30ml of protein G
magnetic beads (Cell signaling Co., Ltd) in the presence of
5mg rabbit IgG for 1h at 4 C with agitation and then was
incubated with 5mg antibodies speciﬁc to SOX9
(Millipore, AB5809) or rabbit IgG for control overnight
at 4 C with rotation. The immunocomplexes were
absorbed with 30ml of protein G magnetic beads and
washed with the buﬀers as described in manufacturer’s
protocol (Millipore Co., Ltd). After reverse cross-linking,
ChIP DNA was purifed by phenol/chloroform extraction
followed by ethanol precipitation according to the
manufacturer’s protocol. The ChIP–quantitative PCR
(qPCR) experiments were carried out by SYBR Green
PCR Master Mix and ABI7900HT (Applied Biosystems)
using ChIP DNA as a template. The data was computed
as percent antibody bound per input. The primers speciﬁc
for the 50-end of the luciferase gene (50-TACGACGGTG
GGCTGGCTGAT-30 and 50-GTGTTGGGTGCCCTGT
TCATC-30) and the primers speciﬁc for the cyclin B1 gene
(50-AATCTGAGGCTAGGCTGGCTCTT-30 and 50-CG
ACCAGCCAAGGACCTACA-30) were used for the
qPCR. The results represent the average of three inde-
pendent experiments. The similarity of the expression
levels between wild-type and dimerless mutant SOX9
was veriﬁed by western blotting using anti-SOX9
antibody. b-actin was used as loading control.
RESULTS
Binding of recombinant full-length and mutant SOX9 to
the Col2a1 enhancer
An in-frame deletion of amino acid residues 66–75 in a
conserved region preceding the HMG domain of SOX9
(Figure 1A), which was identiﬁed in a patient presenting
with CD (23), was previously shown to inhibit formation
of a SOX9 dimer on its target DNA, although the mutant
SOX9 bound this DNA as a monomer. We compared the
concentration-dependent binding of puriﬁed recombinant
wild-type SOX9 and the dimerization domain in-frame
deletion mutant to a probe containing pairs of SOX9
binding sites. This DNA probe is located within a previ-
ously characterized chondrocyte-speciﬁc enhancer in
intron 1 of Col2a1. In EMSA with wild-type SOX9, a
slow-migrating complex was observed, corresponding to
a DNA-bound dimer (Figure 1C), whereas the dimeriza-
tion mutant formed a faster moving complex, correspond-
ing to a DNA-bound SOX9 monomer. While formation of
the monomer complex increased linearly at least at the
lower concentrations of mutant SOX9, formation of the
dimer complex increased more slowly with increasing con-
centrations of wild-type SOX9 suggesting a more
sigmoidal-type progression (Figure 1D).
The DNA probe used in EMSA contained a pair of
potential SOX9 binding sites, designated sites 1 and 2, in
the Col2a1 enhancer (Figure 2A). Site 2 diverges from the
consensus SOX recognition sequence (A/T)(A/T)CAA(A/
T)G at a single position and Site 1 at two positions. A
probe with mutations in Site 1 altered the binding of
wild-type SOX9 from dimeric to monomeric binding
with a concomitant reduction of binding to the probe
(Figure 2B, lane 2), whereas a probe with mutations in
Site 2 essentially abolished dimeric binding and also
showed no momomeric binding (Figure 2B, lane 3).
These experiments suggested that Site 1 is a low-aﬃnity
site and Site 2 is a high-aﬃnity monomeric binding site.
This ﬁnding was conﬁrmed by the observation that
mutant SOX9 did not bind to the probe with a mutated
Site 2, but bound as a monomer to the probe with a
mutated Site 1 (Figure 2B, lanes 5 and 6). To identify
diﬀerences in the kinetics of SOX9–DNA complex forma-
tion between the wild-type and mutant SOX9, the
Nucleic Acids Research, 2010,Vol.38, No. 18 6021recombinant polypeptides were incubated with the probe
for increasing periods of time (Figure 3A, left and right
panels). When the formation of DNA–protein complexes
in EMSA was computed, no diﬀerence in the on-rate of
the two proteins was observed when suﬃcient amounts of
SOX9 were added to form a single dimeric–DNA complex
with wild-type SOX9 and a monomer complex with
mutant SOX9 (Figure 3B). We also compared the stability
of wild-type and mutant SOX9 protein–DNA complexes
in EMSA (Figure 3C). When SOX9–DNA complexes
were allowed to form for 2h and were then challenged
by a 25-fold excess of the non-radiolabeled probe, about
50% of the original complexes were still present 60min
later (Figure 3D). These results showed that both
wild-type and mutant SOX9 proteins have similar
oﬀ-rates under these conditions.
Activation of a Col2a1 promoter/enhancer by recombinant
SOX9 in an in vitro transcription system
Previous transient transfection experiments have shown
that Col2a1 promoter/enhancer constructions were
activated in BALB3T3 and other ﬁbroblast lines when
cotransfected with a SOX9 expression vector (12). To
learn more about how SOX9 activates transcription, we
determined whether recombinant SOX9 could activate
transcription in a cell-free system. In vitro transcription
experiments were performed by adding HeLa nuclear
extracts to a naked DNA template, p89/(4 48bp),
which consisted of a minimal mouse Col2a1 promoter
( 89 to +6) preceded by a 4-fold tandem repeat of a
48-bp segment in intron 1 of Col2a1 (Figure 4A). A
control Col3a1 promoter that is not responsive to SOX9
was also added to the reaction for normalization. In trans-
fection experiments, the activity of the Col2a1 vector was
strongly enhanced by cotransfection with SOX9 (12). A
vector, in which four tandem copies of the 48-bp Col2a1
enhancer in intron 1, placed 30 to a Col2a1 fragment con-
taining 309bp of the promoter, 237bp of exon 1, and
70bp of the intron 1 linked to the lacZ gene, showed
chondrocyte-speciﬁc activity in transgenic mice (13). A
mutation in the 48-bp sequence of this transgene abolished
SOX9 binding and also abolished chondrocyte-speciﬁc
activity in transgenic mice. Both wild-type and mutant
recombinant SOX9 polypeptides activated transcription
of the p89/4 48bp Col2a1 template. Note that the level
of transcription with wild-type SOX9 compared to mutant
SOX9 was very similar at the lower concentration and
slightly greater (1.2-fold) at the highest concentration
(Figure 4B and C).
The dimerization domain of SOX 9 is required for SOX9
to activate chromatin-mediated transcription of Col2a1
To determine whether SOX9 could overcome the repres-
sive eﬀect of nucleosomes in a chromatin template, the
p89/(4 48bp) Col2a1 DNA was assembled into nucleo-
somes by mixing the DNA with histones and Drosophila
embryo S190 extract (Figure 5A). The formation of nu-
cleosomes was veriﬁed by Mnase digestion of the chroma-
tin template, which produced a DNA ladder of multiples
of 146bp, indicating that a regularly spaced nucleosomal
array had formed on the DNA similar to what is found
in vivo (Figure 5B). Addition of wild-type SOX9 either
before or after assembly of nucleosomes stimulated tran-
scription between 4- and 5-folds. In contrast, mutant
SOX9 did not activate transcription of the chromatin
DNA template. This strongly suggested that in the
context of chromatin DNA only SOX9 polypeptides that
form dimers on DNA could activate transcription. The
same result was obtained whether mutant SOX9 was
added before or after chromatin assembly (Figure 5C, D
and E).
The dimerization domain of SOX9 is required for SOX9
to remodel chromatin
To determine whether SOX9 was able to remodel chroma-
tin, we employed a partial Mnase assay using p89/
4 48bp nucleosomal DNA in presence of SOX9. The
Mnase-digested DNA was then analyzed by linear ampli-
ﬁcation using a radiolabeled primer that hybridized to the
luciferase reporter gene in the template. Upon addition of
wild-type SOX9 to the chromatin template, increased
Mnase cleavage was observed at several discrete sites in
the multimerized Col2a1 enhancer region, suggesting that
the nucleosomal structure was disrupted by the binding of
SOX9 to the enhancer (Figure 5F, lanes 2 and 3). In
contrast, addition of mutant SOX9 did not increase
Mnase digestion at these speciﬁc sites, suggesting that
A
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Figure 2. Comparison of DNA binding of puriﬁed wild-type and
mutant SOX9 proteins to the Col2a1 enhancer harboring mutations
in SOX9 binding Sites 1 and 2. (A) Wild-type and mutant Col2a1
probes for which the upper strand of the wild-type sequence is
shown. Sites 1 and 2 correspond to 7-bp HMG-like binding sites.
Mutated nucleotides in Sites 1 and 2 are indicated. (B) EMSA with
wild-type and mutant probes using recombinant wild-type and dimer-
ization mutant SOX9.
6022 Nucleic Acids Research, 2010,Vol.38, No. 18mutant SOX9 did not disrupt the chromatin structure
(Figure 5F, lanes 4 and 5).
In a control experiment, we tested the transactivation
potential of wild-type SOX9 in an in vitro transcription
system, in which the chromatin DNA template carried
mutations in the SOX9 binding site (Figure 6A), muta-
tions that have been shown previously to completely
inhibit DNA binding of SOX9. With the nucleosomal
p89/4 48bp Col2a1 DNA template carrying these muta-
tions both activation of transcription and disruption of
the chromatin template by wild-type SOX9, at the
highest concentration used in Figure 6B, were abolished
(Figure 6C, lane 2 and Figure 6D, lane 4).
In parallel experiments, we generated cell lines in which
a similar Col2a1 vector as the one used for our in vitro
experiments was stably transfected in the genome of 293T
cells. This should produce a situation somewhat analo-
gous to the one produced by the nucleosomal template
in vitro. Transient transfection with increasing amounts
of wild-type SOX9 strongly stimulated the activity of the
Col2a1 promoter/enhancer-luciferase vector. In contrast,
stimulation by the mutant SOX9 was markedly reduced
(Figure 7A). We then performed a chromatin IP experi-
ment using SOX9 antibodies to test whether there was a
diﬀerence in the levels of interaction of SOX9 with the
chromatin of the stably integrated Col2a1 promoter/
enhancer vector in the same cells transfected with either
wild-type or mutant SOX9. Our results indicated that the
degree of occupancy of either wild-type or mutant SOX9
in the chromatin of the stably integrated Col2a1
promoter/enhancer were very similar. Thus in the cells in
which wild-type SOX9 caused a much stronger activation
of the Col2a1 promoter/enhancer-luciferase than the
mutant SOX9, interactions of the wild-type and mutant
SOX9 with the chromatin of this Col2a1 promoter/
enhancer were not diﬀerent.
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Figure 3. Comparison of on-rates and DNA binding stability of wild-type and mutant SOX9 proteins. (A) Comparison of the on-rate of wild-type
and mutant SOX9 binding. Wild-type and mutant SOX9 proteins were incubated for indicated lengths of time with the 31-bp Col2a1 probe. Aliquots
were removed from the reaction at the indicated times and analyzed in EMSA. (B) Amounts of protein–DNA complexes present at each timepoint
were measured using a Phosphoimager and plotted as percentage of the complexes found at the end of the 2-h incubation. Similar results were
obtained in three diﬀerent experiments. (C) Comparison of the stability of wild-type and mutant SOX9–DNA complexes. SOX9–DNA complexes
were allowed to form for 2h and challenged by a 25-fold excess amount of cold competitor oligonucleotides for indicated lengths of time. Aliquots
were removed from the reaction at the indicated times and analyzed in EMSA. (D) Amount of protein–DNA complex present at each timepoint was
determined using a Phosphoimager and computed as a percentage of the amount at the time the competitor was added.
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SOX9 heterozygous mutations that cause CD include
nonsense mutations that truncate the polypeptide,
missense mutations in the DNA binding domain that
prevent SOX9 binding, mutations in RNA splice sites,
chromosomal translocations in the upstream regulatory
region that inhibit the level of expression of SOX9 (4,5),
a mutation in a nuclear localization signal, and missense
and in-frame deletion mutations in a dimerization domain
of SOX9 (23,24). This dimerization domain is highly
conserved among the three members of the SOX E
subgroup, SOX8, -9 and -10, and was ﬁrst identiﬁed by
deletion experiments in SOX10 (29). To better understand
the mechanisms by which the dimerization mutations
inhibit the activity of SOX9, we used puriﬁed recombinant
wild-type and dimerization mutant SOX9 to further char-
acterize the DNA binding of wild-type and SOX9 mutants
and to identify the role of these proteins in the activation
of a SOX9-dependent promoter in cell-free transcription
systems.
The concentration dependence of DNA binding of
wild-type and mutant SOX9 to a previously characterized
SOX9-responsive chondrocyte enhancer sequence was
compared. While binding of mutant SOX9 increased
linearly with concentration, formation of a dimeric
wild-type SOX9–DNA complex increased more slowly
suggesting a more sigmoidal pattern, consistent with the
hypothesis that binding of wild-type SOX9 to its recogni-
tion sites in the Col2a1 intron 1 enhancer might be a more
cooperative process. In previous experiments, which also
compared concentration-dependent binding of wild-type
and mutant SOX9 harboring a point mutation in the di-
merization domain to a Col11a2 dimeric binding site, the
diﬀerence in the pattern of concentration-dependent
binding was not as striking (24). Several factors could
account for this discrepancy. Our experiments were per-
formed with puriﬁed recombinant SOX9, whereas the
previous experiments used SOX9 molecules generated by
in vitro transcription–translation. Hence, these SOX9
preparations contained components of reticulocyte
lysates, which might have inﬂuenced binding. Moreover,
the diﬀerence in the sequences of the SOX9 binding sites in
Col11a2 and Col2a1 may also have aﬀected the
concentration-dependent binding.
Analysis of binding of wild-type and mutant SOX9 to
Col2a1 DNA probes containing mutations in one or the
other half of the dimeric binding site suggests that Site 2 is
a higher aﬃnity monomeric binding site than Site 1. In
addition, higher concentrations of wild-type SOX9 are
needed for stable binding than are needed for the mutant.
The on-rate of binding at concentrations of the protein
at which the wild-type SOX9 bound almost exclusively as
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Figure 4. Transactivation of naked Col2a1 template by SOX9 proteins in an in vitro transcription system. (A) Schematic of the p89/4 48bp Col2a1
template. Four tandem copies of the 48-bp Col2a1 intron 1 enhancer were cloned upstream of a 95-bp minimal Col2a1 promoter ( 89/+6) in a
luciferase reporter plasmid. (B) The p89/4 48bp Col2a1 promoter was transcribed in an in vitro transcription experiment as naked plasmid DNA.
The DNA was added to the transcription mix together with HeLa nuclear extract. Increasing amounts of recombinant wild-type (wt) SOX9 or
mutant SOX9 proteins were added as indicated above the lanes. The Col3a1 promoter was used as an internal control. RNAs were analyzed by
primer extension. The two transcription start sites of p89/4 48bp are indicated. Similar results were obtained in three diﬀerent experiments. (C)
Amount of cDNA transcripts obtained after primer extension was determined using a Phosphoimager, and the values were corrected for the control
DNA Col3a1 and compared to the sample with no SOX9 (*P 0.05, t-test). Both wild-type and mutant SOX9 activated transcription. At the
concentration of 0.33mM, the level of transcription was slightly greater with wild-type SOX9 than with mutant SOX9.
6024 Nucleic Acids Research, 2010,Vol.38, No. 18a dimer and the stability of the DNA–SOX9 complexes
were very similar for the wild-type and mutant proteins.
Previous experiments with SOX10 proteins compared the
on-rate of binding of a truncated SOX10 that contained
both the DNA binding and the dimerization domains of
SOX10 and that of a SOX10 protein containing only the
HMG DNA binding domain (29). In these experiments,
the on-rate reached a maximum within 1min with both
proteins, whereas in our experiment binding with either
full-length wild-type or mutant SOX9 had not yet
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Figure 5. Transactivation of chromatin Col2a1 template by SOX9 proteins in an in vitro transcription system. (A) Sequential steps for in vitro
chromatin assembly and in vitro transcription. (B) Nucleosomal DNA templates were digested with Mnase. The DNA fragments were isolated and
separated on a 1.5% agarose gel and visualized by ethidium bromide staining. A 1kb ladder was used as a molecular weight marker (M). (C, D) The
p89/4 48bp Col2a1 promoter was transcribed in an in vitro transcription system after assembly in a nucleosomal DNA template. Nucleosomal
DNA was added to the transcription mix together with HeLa nuclear extracts. Increasing amounts of recombinant wild-type (wt) or mutant SOX9
proteins were added prior to or after chromatin assembly, as indicated. A plasmid containing the Col3a1 promoter used as an internal control was
added after nucleosomal assembly and hence transcribed as naked DNA. RNAs were analyzed by primer extension. The two transcription start sites
of p89/4 48bp are indicated. Similar results were obtained in three diﬀerent experiments. (E) Amount of DNA obtained after primer extension was
determined using a Phosphoimager, and the values were corrected for the control DNA Col3a1 and compared to the sample with no SOX9 (**P  
0.01, t-test). Wild-type SOX9 at the concentration of 0.23mM clearly activated transcription, but no activation occurs with mutant SOX9. (F) The
dimerization domain of SOX9 is needed to disrupt chromatin Col2a1 DNA. Sox9 proteins were added to the DNA before chromatin assembly.
Nucleosomal DNA templates were then digested with Mnase. The digested DNA was subjected to linear ampliﬁcation and analyzed on a 6%
sequencing gel. Location of the four copies of the 48-bp enhancer is indicated. Filled dots represent hypersensitive bands generated by interactionso f
SOX9 with the enhancer.
Nucleic Acids Research, 2010,Vol.38, No. 18 6025reached maximal binding even after 2h. This diﬀerence
might be attributable to the diﬀerences in experimental
conditions.
To reproduce the activation of chondrocyte-speciﬁc
genes by SOX9 in a cell-free system, we used recombinant
SOX9, a Col2a1 template consisting of multimerized
SOX9 binding sites and a HeLa cell nuclear extract that
did not contain SOX9. When a naked DNA template was
used, somewhat unexpectedly both wild-type and mutant
SOX9 stimulated transcription, indicating that the dimer-
ization domain is not needed to activate transcription.
However, when the transcriptional activities of wild-type
and mutant SOX9 were compared using the same template
assembled into nucleosomes only the wild-type SOX9
activated transcription, whereas the mutant SOX9 was
completely inactive. We propose that the reason for this
inactivity is that, unlike wild-type SOX9, the mutant
SOX9 was unable to eﬃciently disrupt the chromatin,
which is likely to be needed for transcription once
challenged by the assembly of nucleosomes on the
template. This inability to disrupt chromatin occurred
despite the ability of mutant SOX9 to stably bind to
naked DNA, when this complex was challenged with
excess DNA containing a SOX9 binding site.
In previous transient expression experiments reported
by others, the ability of mutant SOX9 with mutations in
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Figure 7. ChIP analysis of the occupancy by SOX9 of a stably
integrated Col2a1 reporter in 293T cells. (A) The stably transfected
Col2a1 reporter is strongly activated by wild-type (wt) SOX9.
Promoter activities are measured as luciferase units (  10
4) and are
given as average values ±SD for triplicate transfections of one repre-
sentative experiment. No signiﬁcant activation was observed with
mutant SOX9 or in the control with no SOX9. (B) In this cell line,
the protein levels of SOX9 were similar 40h after transient transfection
with wild-type (wt) SOX9 or mutant SOX9 as shown in a western blot
probed with SOX9 antibody. (C) ChIP–qPCR analysis. The 293T cells
in which the SOX9-dependent Col2a1 reporter construct was stably
integrated were transfected with wild-type or mutant SOX9 and
ChIP–qPCR analysis was performed as described in ‘Material and
Methods’ section. The data represent the ratio of target fragment to
input DNA. Probes corresponding to the 50 part of the luciferase gene,
located at a distance of approximately 200 to 300bp from the SOX9
binding sites were used for qPCR. The DNA fragment size used for
ChIP was about 500bp. The cylin B1 gene was used as a ChIP–qPCR
negative control. In cells transfected with both wild-type and mutant
SOX9, the amount of speciﬁc DNA precipitated by SOX9 antibodies
was more than 8-fold higher than that precipitated by IgG.
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Figure 6. Mutations in Site 2 of the Col2a1 enhancer abolish transac-
tivation by SOX9. (A) Schematic representation of Col2a1 construct,
p89/4 48bp and mutant p89/4 48bp. Nucleotides corresponding to
the four potential SOX9 binding sites are underlined. Mutations that
abolish SOX9 binding, are indicated. (B) The wild-type p89/4 48bp
Col2a1 promoter was transcribed in an in vitro transcription experiment
as chromatin-assembled DNA. The DNA was added to the transcrip-
tion mix together with HeLa nuclear extract. The plasmid with the
Col3a1 control promoter was added after nucleosomal assembly and
transcribed as naked DNA. RNAs were analyzed by primer extension.
SOX9 was added to DNA prior to chromatin assembly. The two tran-
scription start sites of p89/4 48bp are indicated. (C) The mutant p89/
4 48bp Col2a1 template was transcribed as chromatin-assembled
DNA. Recombinant SOX9 was added to DNA prior to chromatin
assembly. (D) SOX9 was added to the DNA before chromatin
assembly. Nucleosomal DNA templates were then digested with
Mnase and the DNA subjected to linear ampliﬁcation and analyzed
on a 6% sequencing gel. Location of the four copies of the 48-bp
enhancer is indicated. Open dots represent hypersensitive bands
generated by interaction of SOX9 with the enhancer.
6026 Nucleic Acids Research, 2010,Vol.38, No. 18the dimerization domain to activate chondrocyte-speciﬁc
reporters was markedly reduced (23,24). Our experiments
with a cell line in which the Col2a1 vector was stably
integrated conﬁrmed these results and showed that the
mutant SOX9 was unable to activate transcription. In
contrast, in ChIP experiments using the same cell line,
no diﬀerences were seen in the interaction of wild-type
and mutant SOX9 with the chromatin of the stably
integrated Col2a1 promoter/enhancer vector. Thus, we
speculate that despite a similar degree of occupancy of
wild-type and mutant SOX9 on the chromatin of the
Col2a1 template in vivo, other chromatin changes need
to occur for transcription activation. We hypothesize
that the diﬀerences that were observed in the Mnase
assay between wild-type and mutant SOX9 in vitro corres-
pond to the inability of mutant SOX9 to bring about these
changes.
Finally, since the SOX9 dimerization mutant was able
to activate transcription of reporters containing promoters
that are targets of SOX9 in Sertoli cells (23,24), one can
speculate that in these promoters the other proteins
present in Sertoli cells are required to assist SOX9 in
producing changes in chromatin.
In summary, our experiments suggest new insights into
the molecular mechanisms, which are responsible for the
skeletal symptoms of the disease CD caused by mutations
in the dimerization domain of SOX9.
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